Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01507285 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and tolerability of the drug liraglutide in healthy volunteers and people with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 24 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 1999-08 · est. completion 1999-11

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT01507285 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with type 2 diabetes.

Treatments tested

liraglutide also known as NNC 90-1170 Drug

Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
placebo Drug

Initial single dose followed by subsequent multiple s.c. (under the skin) doses

Main thing measured	Area under the Curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01507285 ↗